Activist hedge fund manager Bill Ackman is bringing his sometimes bare-knuckle expertise at the takeover game to Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) as the highly efficient roll-up company targets Botox wrinkle treatment company Allergan, Inc. (NYSE:AGN) with a takeover offer. Activist hedge fund with successful track record at “encouraging” boards to make the “right” decisions teams with Valeant to acquire Allergan The Wall Street Journal is reporting that Ackman’s Pershing Square Capital Management has acquired $4 billion in Allergan, Inc. (NYSE:AGN) stock, making this the fund’s largest investment in its history. According to a CNBC report, Valeant Pharmaceuticals Intl Inc…
Ackman And Valeant Team Up To Pursue Takeover Of Allergan
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.